Neurotoxicity of cancer treatment: Neurocognitive dysfunction and underlying mechanisms

Neurotoxicity of cancer treatment: Neurocognitive dysfunction and underlying mechanisms - Neurotoxicity of cancer treatment

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON29855

Enrollment

338

Registered

2006-10-30

Start date

2006-11-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute lymphoblastic leukemia (ALL) blood cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Being treated for ALL according to DCLSG protocol ALL 5 (1979 - 1984) or according to DCLSG protocol ALL 6 (1984 - 1988)

Exclusion criteria

Exclusion criteria: Use of centrally acting drugs, active psychiatric disease or symptoms, pre-existing CNS disorders, insufficient mastery of Dutch language.

Design outcomes

Primary

Measure	Time frame
Outcomes will be a neuropsychological deficit profile, a profile of structural and functional integrity of neural networks and descriptions of quality of life. Profiles of the different patient groups and controls will be contrasted.	—

Secondary

Measure	Time frame
Coincidental findings of secundary tumors after radiation will be registered.	—

Countries

Netherlands

Outcome results